

References

1. Gutmann D et al. Neurofibromatosis type 1. *Nat Rev Dis Primers* 2017; 3(17004).
2. Blakeley J, Plotkin S. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. *Neuro-Oncology* 2016; 18(5): 624–638.
3. Hsieh DT. Neurofibromatosis Type 1. Medscape 26 Feb 2025. Available at <https://emedicine.medscape.com/article/1177266-overview>. Accessed April 2025
4. Ferner R, Huson SM, Thomas N et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *Journal of Medical Genetics* 2007; 44: 81–88.
5. NHS England. National Genomics Education Programme. Neurofibromatosis type 1. 23 March 2023. Available at: <https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/neurofibromatosis-type-1/>. Accessed Feb 2025
6. Nerve Tumours UK. Information about localised, segmental or mosaic Neurofibromatosis type 1 (NF1) (download) [No date]. Available at: https://nervetumours.org.uk/images/downloads/Segmental_or_mosaic_NF1_v1.pdf. Accessed Feb 2025
7. Mayo Clinic Staff. Neurofibromatosis type 1. Mayo Clinic [No date]. Available at: <https://www.mayoclinic.org/diseases-conditions/neurofibromatosis-type-1/symptoms-causes/syc-20350490>. Accessed Feb 2025
8. Victorio MC. Neurofibromatosis. MSD Manual. Nov 2023. Available at <https://www.msmanuals.com/en-gb/professional/pediatrics/neurocutaneous-syndromes/neurofibromatosis>. Accessed Feb 2025
9. Alves Júnior SA et al. Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement. *Respiratory Medicine* 2019;149:9-15.
10. Bergoug M et al. Neurofibromin structure, functions and regulation. *Cells* 2020;9(11):2365.
11. Lee T-SJ et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. *Orphanet J Rare Dis* 2023; article 292. Available at: <https://ojrd.biomedcentral.com/articles/10.1186/s13023-023-02911-2>. Accessed Feb 2025
12. Bostock N. Average GP patient list hits 10,000 in landmark shift for general practice. *GPonline* 15 Feb 2024. Available at: <https://www.gponline.com/average-gp-patient-list-hits-10000-landmark-shift-general-practice/article/1861611>. Accessed Feb 2025
13. Biotteau M et al. Sporadic and familial variants in NF1: And explanation of the wide variability in neurocognitive phenotype? *Front Neurol* 6 May 2020. Available at: <https://pubmed.ncbi.nlm.nih.gov/32431664/>. Accessed Feb 2025
14. Ly KI, Blakeley J. The diagnosis and management of neurofibromatosis Type 1. *Medical Clinics of North America* 2019; 103(6): 1035-1054.
15. NHS. Neurofibromatosis type 1. 9 April 2025. Available at: <https://www.nhs.uk/conditions/neurofibromatosis-type-1/>. Accessed April 2025
16. Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic *NF1* gene variants. *Hum Genet* 2021;141(2):177-191.
17. Friedman JM. Neurofibromatosis 1. In: Adam MP, Feldman J, Mirzaa GM et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. October 1998; updated April 2022. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1109/>. Accessed February 2025
18. Patient Professional. Neurofibromatosis. 28 July 2021. Available at <https://patient.info/doctor/neurofibromatosis-pro>. Accessed Feb 2025
19. Miller D et al. Health supervision for children with neurofibromatosis type 1. *Pediatr* 2019; 143(5): e20190660.
20. Oostenbrink R et al. Neurofibromatosis type 1: Burden of disease in patients with plexiform neurofibromas. *Eur Med J* 9 December 2021. Available at: <https://www.emjreviews.com/oncology/symposium/neurofibromatosis-type-1-burden-of-disease-in-patients-with-plexiform-neurofibromas-j190421>. Accessed Feb 2025
21. Skorobogatko A, Umphress BA. Plexiform neurofibroma. *PathologyOutlines.com*. 28 September 2023. Available at: <https://www.pathologyoutlines.com/topic/softtissueurofibromaplexiform.html>. Accessed Feb 2025

References

22. Lubs M-L et al. Lisch nodules in neurofibromatosis type 1. [NEJM 1991;324\(18\):1264-1266.](#)
23. Mallone F et al. An update on choroidal abnormalities and retinal microvascular changes in neurofibromatosis type 1. *Orphanet J Rare Dis* 2022; article223. Available at: <https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02369-8>. Accessed Feb 2025
24. Botero V, Tomchik SM. Unraveling neuronal and metabolic alterations in neurofibromatosis type 1. [J Neurodevelopmental Disorders 2024;16:49.](#)
25. Vernet M et al. Visual-processing deficits in children with neurofibromatosis type 1: A clinical marker of reading difficulties. [Eur J Paediatr Neurol 2022;38:25-32.](#)
26. Lehtonen A et al. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. [Dev Med & Child Neurol 2023;55:111-125.](#)
27. Garf S et al. Autism spectrum disorder profile in neurofibromatosis type 1. [J Autism Dev Disord 2015;45\(6\):1649-57.](#)
28. National Organization for Rare Diseases. Neurofibromatosis 1. April 2022. Available at: <https://rarediseases.org/rare-diseases/neurofibromatosis-type-1-nf1/>. Accessed Feb 2025
29. de Blank PMK et al. Optic pathway gliomas in neurofibromatosis type 1: An update: surveillance, treatment indications, and biomarkers of vision. [J Neuroophthalmol 2017;37\(1\):S23-S32.](#)
30. Nerve Tumours UK. Bone changes in neurofibromatosis type 1 (download) [No date]. Available at: https://nervetumours.org.uk/images/downloads/Bone_changes_in_Neurofibromatosis_Type_1_March_2015_v1.pdf. Accessed Feb 2025
31. Javed F et al. Oral manifestations in patients with neurofibromatosis type-1: A comprehensive literature review. *Critical Reviews in Oncology/Hematology* 2014;91(2):123-129
32. Chinoy A et al. The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective. [J Musculoskeletal Interact 2022;22\(1\):70-78.](#)
33. NHS Guy's and St Thomas'. Overview. Neurofibromatosis type 1 and itching. July 2024. Available at: <https://www.nfmidwest.org/wp-content/uploads/2017/07/Medical-Imaging-for-Adults-with-Neurofibromatosis-type-1.pdf>. Accessed March 2025
34. Friedman JM et al. Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force. [Genetics in Medicine 2002;4\(3\):105-111](#)
35. Landry JP et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs. in the general population from 1985 to 2020. [JAMA Netw Open 2021;4\(3\):e210945.](#)
36. Carton C et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. [eClinicalMedicine 2023;56:101818.](#)
37. Girma T et al. Unusual presentation of GIST associated with type 1 neurofibromatosis: A case report. [Int J Surgery Case Reports 2023;105:107992.](#)
38. Goetsch A. Medical imaging for NF1: Radiation exposure. Neurofibromatosis Midwest. Be iNformed. August 2017. Available at: <https://www.nfmidwest.org/wp-content/uploads/2021/04/Medical-Imaging-for-Adults-with-Neurofibromatosis-type-1.pdf>. Accessed March 2025
39. Madubata CC et al. Neurofibromatosis type 1 and chronic neurological conditions in the United States: An administrative claims analysis. [Genet Med 2014;17\(1\):36-42.](#)
40. Terry AR et al. Neurofibromatosis type 1 and pregnancy complications: a population-based study. [Am J of Obstetr and Gynecol 2013;209:46.E1-46.E8.](#)
41. Legius E et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. [Genet Med 2021;23:1506-13.](#)
42. Neurofibromatosis type 1 (syn. Von Recklinghausen's disease). Primary Care Dermatology Society. September 2022. Available at: <https://www.pcds.org.uk/clinical-guidance/neurofibromatosis-type-1#management>. Accessed March 2025